Joel N. Buxbaum - Search Results

Year	Number of Results
2002	1
2003	2
2004	5
2005	2
2006	4
2007	5
2008	2
2009	2
2010	1
2011	4
2012	4
2013	3
2014	2
2015	4
2016	6
2017	5
2018	5
2019	4
2020	2
2021	6
2022	5
2023	2
2024	0

1

Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee.

Buxbaum JN, Dispenzieri A, Eisenberg DS, Fändrich M, Merlini G, Saraiva MJM, Sekijima Y, Westermark P. Buxbaum JN, et al. Amyloid. 2022 Dec;29(4):213-219. doi: 10.1080/13506129.2022.2147636. Epub 2022 Nov 24. Amyloid. 2022. PMID: 36420821

2

Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee.

Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, Sipe JD, Westermark P. Benson MD, et al. Among authors: buxbaum jn. Amyloid. 2020 Dec;27(4):217-222. doi: 10.1080/13506129.2020.1835263. Epub 2020 Oct 26. Amyloid. 2020. PMID: 33100054

3

Stress-responsive regulation of extracellular proteostasis.

Mesgarzadeh JS, Buxbaum JN, Wiseman RL. Mesgarzadeh JS, et al. Among authors: buxbaum jn. J Cell Biol. 2022 Apr 4;221(4):e202112104. doi: 10.1083/jcb.202112104. Epub 2022 Feb 22. J Cell Biol. 2022. PMID: 35191945 Free PMC article. Review.

4

Oligonucleotide Drugs for Transthyretin Amyloidosis.

Buxbaum JN. Buxbaum JN. N Engl J Med. 2018 Jul 5;379(1):82-85. doi: 10.1056/NEJMe1805499. N Engl J Med. 2018. PMID: 29972750 No abstract available.

5

The aging transcriptome: read between the lines.

Perez-Gomez A, Buxbaum JN, Petrascheck M. Perez-Gomez A, et al. Among authors: buxbaum jn. Curr Opin Neurobiol. 2020 Aug;63:170-175. doi: 10.1016/j.conb.2020.05.001. Epub 2020 Jun 17. Curr Opin Neurobiol. 2020. PMID: 32563038 Free PMC article. Review.

6

A molecular history of the amyloidoses.

Buxbaum JN, Linke RP. Buxbaum JN, et al. J Mol Biol. 2012 Aug 10;421(2-3):142-59. doi: 10.1016/j.jmb.2012.01.024. Epub 2012 Feb 1. J Mol Biol. 2012. PMID: 22321796 Review.

7

Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation.

West J, Satapathy S, Whiten DR, Kelly M, Geraghty NJ, Proctor EJ, Sormanni P, Vendruscolo M, Buxbaum JN, Ranson M, Wilson MR. West J, et al. Among authors: buxbaum jn. Sci Adv. 2021 Dec 10;7(50):eabf7606. doi: 10.1126/sciadv.abf7606. Epub 2021 Dec 10. Sci Adv. 2021. PMID: 34890220 Free PMC article.

8

Transthyretin: the servant of many masters.

Buxbaum JN, Reixach N. Buxbaum JN, et al. Cell Mol Life Sci. 2009 Oct;66(19):3095-101. doi: 10.1007/s00018-009-0109-0. Epub 2009 Jul 31. Cell Mol Life Sci. 2009. PMID: 19644733 Free PMC article. Review.

9

The systemic amyloidoses.

Buxbaum JN. Buxbaum JN. Curr Opin Rheumatol. 2004 Jan;16(1):67-75. doi: 10.1097/00002281-200401000-00013. Curr Opin Rheumatol. 2004. PMID: 14673392 Review.

10

Oligonucleotide Drugs for Transthyretin Amyloidosis.

Buxbaum JN. Buxbaum JN. N Engl J Med. 2018 Nov 22;379(21):2086. doi: 10.1056/NEJMc1810994. N Engl J Med. 2018. PMID: 30462941 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

72 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year